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Abstract
Background: Gene expression profiles based on microarray data have been suggested by many
studies as potential molecular prognostic indexes of breast cancer. However, due to the
confounding effect of clinical background, independent studies often obtained inconsistent results.
The current study investigated the possibility to improve the quality and generality of expression
profiles by integrated analysis of multiple datasets. Profiles of recurrence outcome were derived
from two independent datasets and validated by a third dataset.
Results: The clinical background of patients significantly influenced the content and performance
of expression profiles when the training samples were unbalanced. The integrated profiling of two
independent datasets lead to higher classification accuracy (71.11% vs. 70.59%) and larger ROC
curve area (0.789 vs. 0.767) of the testing samples. Cell cycle, especially M phase mitosis, was
significantly overrepresented by the 60-gene profile obtained from integrated analysis (p < 0.0001).
This profiles significantly differentiated poor and good prognosis in a third patient cohort (p =
0.003). Simulation procedures demonstrated that the change of profile specificity had more instant
influence on the performance of expression profiles than the change of profile sensitivity.
Conclusion: The current study confirmed that the gene expression profile generated by
integrated analysis of multiple datasets achieved better prediction of breast cancer recurrence.
However, the content and performance of profiles was confounded by clinical background of
training patients. In future studies, prognostic profile applicable to the general population should be
derived from more diversified and balanced patient cohorts in larger scale.
Background
Breast cancer involves a series of genomic disorders, mak-
ing it a suitable subject of microarray experiments [1].
Mapping microarray-based gene expression profiles to
clinical phenotypes has been proposed as a solution to
improve cancer diagnosis and prognosis [2]. A number of
such profiles, which are able to distinguish cell lines [3],
normal and tumor tissues [4], adjacent tumors [5], and
tumor subtypes [6,7], have been presented. Expression
profiles of cancer endpoints are more valuable in clinical
practice. From a microarray dataset of 78 breast cancer
patients, van 't Veer et al identified a 70-gene profile that
correctly classified 5-year recurrence of 65 (83%) patients
[8]. This profile was further proved to be superior to cur-
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by other studies [10-12]. However, these profiles shared
little overlap with each other. It was further noticed that
highly distinct profiles had similar performance and sig-
nificant agreement on recurrence prediction [13,14].
These observations indicate that the expression profiling
of cancer prognosis is more complicated than simply
identifying a list of differentially expressed genes from a
single dataset.
Despite of the prospective benefits, key issues related to
expression profiling of cancer prognosis still remain in
question. First, it should be presumed that the classifica-
tion of patient prognostic groups properly reflects the
inherent difference between their gene expression pat-
terns. Studies usually dichotomize breast cancer patients
according to clinically used 5-year prognosis [8,10]. How-
ever, this convention is established by usage rather than
based upon intrinsic biological difference between tumor
cells, and may reduce the statistical power of subsequent
analyses. Retsky et al. discovered that the recurrence of
breast cancer has a two-peak distribution independent of
tumor size, number of positive nodes, and menopause
status [15]. Computer simulation of tumor progression
suggested that two different models of secondary tumor
growth were responsible for this distribution [15,16]. The
18-month peak was the consequence of accelerated sec-
ondary growth stimulated by mastectomy while patients
in the 60-month peak went through steady stochastic
transitions of tumor progression phases.
Another issue is the influence of clinical confounders,
such as ER and lymph node status. Gruvberger et al
noticed that 165 of the 231 genes top-ranked in van 't Veer
paper were also significantly correlated to ER status of
patients [17,18]. It was then suggested that expression
profiling should be carried out for ER-positive and -nega-
tive patients separately. Expression profile derived from
one patient cohort might not be applicable to other
cohorts having dissimilar clinical background. Removing
or reducing the confounding effect will improve the
robustness of expression profiles. Nevertheless, the sug-
gestion of Gruvberger et al may not be a practical solution
because there are many known and unknown confound-
ers intervening in the correlation between gene expression
level and breast cancer recurrence.
Furthermore, comparing to the large number of genes
(variables) measured by microarray experiments, sample
sizes are usually too small to give enough statistical
power. Consequently, gene expression profiles unavoida-
bly include false positives due to 'multiple hypothesis test-
ing' [19] while many differentially expressed genes will
not be identified due to lack of statistical power. A ques-
tion worthy of more discussion is how sensitivity and spe-
cificity should be optimally balanced in expression
profiles.
Integrated analysis of multiple independent microarray
datasets has drawn noteworthy interests recently [20-22].
Not only will this strategy increase the overall statistical
power of expression profiling, but also it can reduce the
influence of confounders by including diversified sam-
ples. Genes directly and consistently, but not obviously,
correlated to disease outcome will be preferred by inte-
grated analysis. A basic assumption of integrated analysis
is that independently generated datasets may share com-
mon information despite of systematic variations
between experiments. Ghosh et al investigated the consist-
ence of four independent microarray datasets from pros-
tate cancer [21]. Meta-analysis of those datasets concluded
that their gene expression profiles are significantly similar
to each other. Rhodes et al compared the expression pro-
files of normal and tumor cells in a larger scale using 21
datasets from 12 tissue types [22]. 67 genes consistently
correlated to the normal-tumor phenotypes across data-
sets were proposed as a generic expression profile of neo-
plastic transformation.
The aim of this study is to improve the expression profil-
ing of breast cancer recurrence by integrating independent
datasets. Breast cancer patients were classified according
to Retsky recurrence model. Expression profiles derived
from two individual datasets and their integration were
objectively compared by random re-sampling and cross-
validation. It was demonstrated that the expression pro-
files had higher specificity after datasets were integrated.
Furthermore, the resultant expression profiles were vali-
dated by a third dataset.
Results
SEP (Score for Expression Profile) as a prognosis index of 
breast cancer
According to the original study using Rosetta dataset, the
expression level of 231 genes was significantly correlated
(|r| > 0.3, p < 0.01) to 5-year recurrence of 78 breast cancer
patients [8]. SEP scores were calculated using those
patients and genes while the expected expression level (Ei)
of each gene in formula (1) was set to zero and the weight
(wi) was set to the Pearson correlation coefficient (r)
between gene expression and 5-year recurrence outcome
[see Additional file 1]. Fig. 1A plots the density distribu-
tion of resultant 78 scores, which has a surprising three-
peak model. The score distributions of two prognosis
groups are separately plotted in Fig. 1B, which indicates
that the right and middle peaks in Fig. 1A are mainly com-
posed of poor and good prognosis patients respectively
while the left peak was a mixture of both. It was also
noticed that patients having the lowest SEP scores (leftPage 2 of 13
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patients were mostly ER-positive (54 of 65).
Fisher's exact test was used to evaluate the dependence of
SEP on major clinical indexes after patients were equally
separated into high score and low score groups with the
threshold equal to median score. The results showed that
the values of SEP were significantly dependent on ER sta-
tus (positive vs. negative), PR status (positive vs. nega-
tive), tumor size (T1 vs. T2) and histological grade (1 vs.
2 vs. 3) with p < 0.001, but not on angioinvasion (positive
vs. negative, p = 0.21) or age of patients (<= 40 vs. >40, p
= 0.61).
Partial correlation analysis was then applied to control
out the confounding effect of ER status. Correlation
between recurrence outcome and residuals obtained from
Formula (2) was calculated and the 127 genes having |r'|
> 0.3 were used to recalculate SEP scores. The score distri-
butions of two prognosis groups are separately plotted in
Fig. 1C. Results of Fisher's exact test showed that modified
SEP was not dependent on ER status (p = 0.21), but still
significantly dependent on histological grade (p < 0.001)
and tumor size (p = 0.006), and marginally on PR status
(p = 0.04).
Analysis of two independent datasets
The current study incorporated permutated re-sampling,
training/testing validation, and stepwise procedure to
objectively compare performance of prognostic expres-
sion profiles. The workflow was first applied to Rosetta
and Stanford datasets separately. Patients in each progno-
sis group of each dataset were randomly re-sampled into
training (about two-thirds of total patients) and testing
(the rest patients) subgroups. The expression profiles were
generated from the training patients and tested by the test-
ing patients. To avoid sampling bias, patients were repeat-
edly re-sampled to obtain different combinations of
training/testing subgroups upon which the following ana-
lytical steps were repeated. After each re-sampling, the dif-
ferential expression of each gene between two prognosis
groups was tested by non-parametric Wilcoxon Rank Sum
Test (RST) [23] using the training data and the resultant Z
statistics was used to rank all 5,569 genes. The gene whose
Z value had the largest magnitude was ranked the highest.
Top-ranked N genes constituted an expression profile.
Increasing the value of N would supposedly improve pro-
file sensitivity, but reduce specificity at the same time. A
stepwise procedure was carried out to find the optimal
balance between specificity and sensitivity of profiles, dur-
ing which top-ranked genes were added one by one until
N = 100. Testing patients were re-scored at each step using
Formula (1), while the weight of each gene equal to its Z
statistic and the expected value equal to the average
expression of that gene in training patients. Testing
patients were classified into two groups using resultant
SEP scores (positive vs. negative). The SEP-based classifi-
cation was matched to actual recurrence outcome to get its
accuracy. To take advantage of SEP as a continuous varia-
ble, scores were also used to build ROC curve and the area
under the curve (AUC) indicated how much the prognosis
groups were differentiated by SEP.
Previous steps were repeated for 10,000 re-samplings. The
upper half of Table 1 shows the median classification
accuracy and ROC curve area achieved by individual data-
sets when N was 100. At each re-sampling, the overall
accuracy and AUC of two datasets were also calculated as
size (of testing subgroups)-weighted averages. The 90% CI
of size-weighted average accuracy and AUC was (61%,
80%) and (0.69, 0.88) respectively. Only eight re-sam-
plings got less than 50% accuracy, giving a permutation p
value equal to 0.0008. Rosetta dataset obtained generally
better results than Stanford dataset, probably because of
Density distribution of SEP scoresFigure 1
Density distribution of SEP scores. SEP of breast cancer 
patients was calculated with microarray data published by 
van' t Veer et al. (A) The distribution of all 78 scores was 
plotted altogether. SEP was calculated with 231 genes corre-
lated to 5-year recurrence outcome with |r| > 0.3 according 
to the original study. (B) The score distributions of 44 good 
prognosis patients and 34 prognosis patients were separately 
plotted. Good prognosis patients were expected to have 
higher SEP scores. (C) The score distributions of good and 
poor prognosis patients were plotted again after confounding 
effect of ER status was removed by partial correlation analy-
sis. SEP was calculated with 127 genes correlated to 5-year 
outcome with |r'| > 0.3.Page 3 of 13
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background of patients.
Fig. 2 plots the median and 90% CI of size-weighted aver-
age AUC when N was 1 till 100. The median AUC went up
dramatically at the beginning of the curve and
approached a plateau when N was about 60, suggesting
that the differential ability of expression profiles was
about to be saturated. Since increasing N would also
increase the ratio of false positives in profiles, it was
empirically decided that the sensitivity and specificity of
expression profiles were optimally balanced at N = 60.
Except when N was very small, the scale of 90% CI did not
change noticeably with N.
A final gene ranking was obtained from each dataset based
on how many times each gene was ranked within top 100
through all re-samplings. The 60 genes having the largest
counts constituted an ultimate expression profile of a
dataset. When these genes were used to calculate SEP
scores, the weight was their RST Z statistics calculated
from all patients in that dataset and the expected expres-
sion was conservatively set to 0 by default. The 60-gene
profiles of both datasets were precise classifiers when they
were self-validated. Rosetta profile had an accuracy of
79.3% and AUC of 0.89, and Stanford profile achieved
82.3% and 0.93 respectively. Although the two profiles
only shared two common genes, BUB1 and LRP8, they
were both cross-validated by the other dataset as satisfying
predictors of 3-year recurrence (Table 2).
The validating SEP was compared to currently used prog-
nostic indexes of breast cancer with logistic regression
models. Table 3 compares the fitness of each model.
When independent variables were used individually,
models built using SEP had the best fitness, followed by
models of histological grade. Multivariate models were
built with all available indexes as independent variables.
Likelihood ratio tests showed that when SEP was removed
from the multivariate model of Rosetta dataset, the model
performance was significantly reduced (p = 0.006); but
did not get similar result from Stanford data (p = 0.15),
probably due to smaller number of samples.
Changing of ROC curve area with size of expression profilesFigure 2
Changing of ROC curve area with size of expression 
profiles. Permutation median (blue line) and 90% CI (orange 
lines) of ROC curve area summarized from two independent 
datasets and 10,000 re-samplings. ROC curves were built 
with SEP scores of testing patients at each re-sampling while 
SEP was calculated with expression profiles identified from 
the training patients. The size of expression profiles was 
increased from 1 to 100 one by one. Average curve area of 
two testing subgroups was weighted by their size.
Table 1: Predictability of expression profiles
Training dataset Tested on Rosetta Tested on Stanford Size-weighted average
Accuracy AUC Accuracy AUC Accuracy AUC
Individual 71.43% 0.775 70.00% 0.764 70.59% 0.767
Combined 71.43% 0.786 71.43% 0.799 71.11% 0.789
At each permutation re-sampling, SEP of testing patients was calculated with top-ranked genes obtained from training patients; the mean of accuracy and 
AUC was weighted by size of testing subgroups; values presented were the medians summarized from10,000 re-samplings.
Table 2: Cross-validation of two independent datasets
Profile Validated by Accuracy AUC Odds 
ratio
Rosetta Stanford 74.2% 0.808 9.06
Stanford Rosetta 70.7% 0.786 6.68
Overall 72.2% 0.795 6.71
SEP scores of validating patients were calculated with the 60-gene 
profile of the validated dataset. Patients were evenly classified into 
two groups using median score as threshold. Accuracy: percentage of 
correctly classified patients; AUC: area of SEP-based ROC curve; 
Odds ratio: the association between SEP and disease outcome based 
on Fisher's exact test.Page 4 of 13
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Stanford datasets. After each re-sampling as described
above, training patients from both datasets were pooled
together and RST was performed on each gene using the
combined data. Genes were ranked by their Z statistics
and top-ranked ones were used to constitute expression
profiles, which would be validated separately by testing
patients of individual datasets. Table 1 summarizes the
median of classification accuracy and AUC with N = 100
and the sized-weighted averages of these statistics were
generally higher than those obtained from the individual
datasets. The median accuracy was slightly raised by
0.52% and the median AUC was more notably raised by
0.022. Five of 10,000 re-samplings got less than 50% clas-
sification accuracy, giving a permutation p value of
0.0005. Fig. 3 plots the median of size-weighted average
AUC against the value of N. The combined dataset always
achieved larger median AUC than the individual ones
when N > 3. At N = 100, the profiles of the combined data-
set outperformed those of individual datasets in about
74% re-samplings.
The count of each gene ranked within top-100 by the
combined dataset was also used to rank genes. Fig. 4 dem-
onstrates the counts of 300 top-ranked genes by two indi-
vidual datasets and the combined dataset. It shows that
the repeatability of ranking genes was generally low. For
example, the 100th gene had less than one-third probabil-
ity to be ranked top-100 by all three datasets. The com-
bined dataset ranked genes relatively more consistently.
The 60th gene was ranked within top-100 by more than
half of the permutations.
Some genes in the 60-gene profiles of three different data-
sets are listed in Table 4 while the complete gene lists are
provided as supplementary data [see Additional file 2].
Two genes (BUB1 and LRP8) were presented in all profiles
while fifteen others (MPL, BECN1, etc.) were only in the
combined dataset profile. These genes were ranked higher
by the combined dataset because of their low inter-dataset
variance. The combined dataset profile included two
known molecular markers of breast cancer: BCL2 and
ESR1.
Among the 60 genes of each profile, the least significant p
value of RST was 0.0002 (Rosetta), 0.0014 (Stanford), or
Consistence of gene ranking across re-samplingsFigure 4
Consistence of gene ranking across re-samplings. The 
counts by which each gene was ranked in top-100 across 
10,000 re-samplings were summarized from both individual 
datasets and the combined dataset. Genes were ranked 
based on their counts and the counts of top-ranked 300 
genes were presented (blue line: Stanford dataset, green line: 
Rosetta dataset, red line: the combined dataset).
Comparison of profiles from individual and combined data-setsFigure 3
Comparison of profiles from individual and combined 
datasets. ROC curves were built with testing SEP scores 
obtained from two individual datasets and their combination. 
The size of expression profiles was increased from 1 to 100 
one by one. Median areas were summarized from 10,000 re-
samplings. Size-weighted average areas achieved by the com-
bined dataset (red line) were generally larger than the corre-
sponding areas achieved by individual datasets (blue line).Page 5 of 13
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discovery rates 0.017, 0.097, or 0.006. The improvement
achieved by the combined dataset indicated that more sta-
tistical power was gained by data integration.
The DAVID functional annotation tool [24] was applied
to the combined dataset profile while all 5,569 Unigene
clusters were used as the genomic background. Some of
the enriched gene sets are listed in Table 5. Cell Cycle,
especially M Phase Mitosis, was the most significantly
overrepresented gene set. Without redundancy, 35 genes
in the profile were included by the gene sets in Table 5. A
complete list of these genes and other enriched gene sets
are available as supplementary materials [see Additional
file 3].
Validation of profiles with a third dataset
The 60-gene profiles obtained from Rosetta and the com-
bined datasets were validated by an independent dataset
generated by Wang et al at Veridex, LLC [25]. This dataset
included 286 lymph node-negative breast cancer patients
within which 209 patients were ER-positive and 106
patients developed recurrence before the end of follow-
up. The source data was downloaded from Gene Expres-
sion Omnibus database (GSE2034) and reprocessed using
the same steps applied to the training datasets. The data
was generated on Affymetrix Human U133A platform,
which included 51 genes of both profiles. These genes and
their weight were used to calculate SEP scores [see Addi-
tional file 4]. Due to the lack of common reference sam-
ples and the difference in array platforms, scores of the
validating patients could not be directly compared to
those of the training patients. Consequently, patients were
conservatively separated into two equal-sized groups
using the median score as threshold. The predictability of
SEP-based classification was evaluated by Cox propor-
tional hazards analysis (Table 6) and Kaplan-Meier sur-
vival analysis (Fig. 5). When all Veridex patients were
used, both profiles significantly differentiated the recur-
rence outcome of high score and low score groups with
very similar hazard ratios. While both profiles performed
better when they were applied to ER-positive patients
only, the combined dataset profile further outperformed
the Rosetta profile.
The correlation of genes in both profiles to 3-year progno-
sis was also validated. In the Veridex dataset, there were 69
patients who developed recurrence within three years and
180 patients who kept recurrence-free during a follow-up
of three years or longer. The rest of the 37 patients were
excluded from the following analyses. Gene differential
expression between two prognosis groups was tested by
Wilcox RST [see Additional file 4]. Respectively 17 and 37
of 51 genes in combined dataset profile had one-sided p
values less than 0.01 and 0.1. All genes except PCTK1 had
the same direction of group difference as expected. In
Rosetta profile, the corresponding numbers were 9 and 28
and there were 7 genes had the opposite direction of
group difference as expected.
With SEP threshold equal to the median of all 286 scores,
the accuracy, specificity, and sensitivity of SEP-based clas-
sification were calculated (Fig. 5). While the overall results
were poorer than the results in Table 2, the combined pro-
file always outperformed Rosetta profile. Fisher's exact test
rejected the independence of 3-year prognosis on both of
combined dataset profile (p = 0.0002, odds ratio = 3.08)
and Rosetta profile (p = 0.0006, odds ratio = 2.82). Nota-
bly, based on both profiles, the 50 patients having the
highest scores only included four poor prognosis cases
(92% specificity) while the expected number was 13.9.
Sensitivity and specificity of expression profiles
The balance between specificity and sensitivity is a major
concern of gene expression profiling. Two simulation pro-
cedures were carried out to evaluate how the change of
sensitivity or specificity will affect the predictability of
profiles.
Table 3: Comparison of prognostic indexes with logistic 
regression models
Rosetta Stanford
-2LL L. R. p value -2LL L. R. p 
value
Intercept 108.7 79.9
SEP 93.1 15.6 0.0001 65.9 14.0 0.0002
ER status 98.0 10.8 0.001 74.3 5.5 0.02
PR status 103.5 5.3 0.02 NA NA NA
Tumor size 101.2 7.6 0.006 76.6 3.3 0.35
Lymph node 
status
NA NA NA 78.2 1.7 0.44
Histological 
grade
92.9 15.9 0.0004 70.4 9.5 0.009
Age at 
diagnosis
98.9 9.8 0.002 78.6 1.24 0.27
Angioinvasion 104.4 4.4 0.04 NA NA NA
Multivariate 
model (include 
SEP)
67.7 41.0 0.000002 54.8 25.1 0.005
Multivariate 
model (not 
include SEP)
75.2 33.6 0.00002 56.9 23.0 0.006
Model fitness was represented by -2LL (-2 log likelihood), L.R. 
(likelihood ratio), and p value. Multivariate models were built with all 
presented indexes with or without SEP. NA: value of index was 
uniform or not given. Two Stanford samples, svcc76 and svn007, were 
not included because of incomplete clinical information.Page 6 of 13
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ity of expression profiles by reducing their size. The per-
mutation re-samplings described above were applied to
Rosetta dataset for another 1,000 times. The top-ranked
60 genes of each re-sampling constituted an initial profile.
A stepwise procedure was applied to the initial profile by
randomly removing three genes at each step until N = 0.
At each reduction step, SEP of testing patients was recalcu-
lated and evaluated as a classifier of 3-year recurrence. Fig.
6 plots the changing median and 90% CI of AUC with the
number of genes removed from the initial profile. The
median AUC kept almost unchanged until N was 42; went
down slightly when N was between 42 and 18; and
dropped more quickly afterwards. The AUC had a median
value of 0.716 when there were only three genes left in the
profile.
The reduction procedure artificially decreased the specifi-
city of expression profiles by substituting top-ranked
genes with false positives. Its only difference to the reduc-
tion procedure was to replace the removed genes by three
other genes randomly selected from all 5,569 genes, keep-
ing the size of expression profiles unchanged. The replac-
ing genes inherited the weight of the replaced genes to
ensure themselves as false positives. Consequently, profile
specificity was gradually decreased until there were only
false positives. Fig. 7 shows the changing of median and
90% CI of AUC with the number of genes replaced. The
median AUC kept stable when only a few genes were
replaced; dropped by about 0.02 when half genes were
replaced; and fell down rapidly afterwards. Furthermore,
the 90% CI was widened with the number of replaced
genes. As expected, the median AUC was about 0.5 when
all 60 genes were replaced.
Discussion
A clinically valuable expression profile of general breast
cancer population, if it does exist, should at least meet two
requirements: it should add extra prognostic value
beyond currently used indexes and it should be independ-
ent of those indexes. This study gave promising, but
inconclusive, results on the first requirement. According
to Table 3 and likelihood ratio test, the difference between
multivariate models with and without SEP was marginally
Table 4: Focus genes in expression profiles of breast cancer outcome
Unigene Symbol Full name Combined 
(count/rank)
Rosetta
 (count/rank)
Stanford 
(count/rank)
Hs.469649 BUB1 BUB1 budding 
uninhibited by 
benzimidazoles 1 
homolog
3/9,681 24/6,547 11/8,047
Hs.576154 LRP8 low density 
lipoprotein receptor-
related protein 8
13/8,428 60/4,211 50/3,858
Hs.496068 PCTK1 PCTAIRE protein 
kinase 1
1/9,862 5/8,768 120/2,261
Hs.523468 SCUBE2 signal peptide, CUB 
domain, EGF-like 2
2/9,732 1/9,991 3,615/1
Hs.523836 GSTP1 glutathione S-
transferase pi
228/989 >3,257/0 1/9,866
Hs.208124 ESR1 estrogen receptor 1 4/9,647 248/1,048 2/9,297
Hs.58974 CCNA2 cyclin A2 9/8,673 698/149 4/8,925
Hs.524134 GATA3 GATA binding protein 
3
10/8,651 99/2,755 25/5,530
Hs.82906 MPL Myeloproliferative 
leukaemia virus 
oncogene
12/8,466 120/2,329 67/3,606
Hs.267659 VAV3 vav 3 oncogene 14/8,415 284/881 20/6,421
Hs.12272 BECN1 beclin 1 (coiled-coil, 
myosin like BCL2 
interacting protein)
18/8,158 74/3,603 96/2,560
Hs.153752 CDC25B cell division cycle 25B 24/7,690 37/5,249 127/2,140
Hs.9589 UBQLN1 ubiquilin 1 25/7,634 7/8,723 824/145
Hs.150749 BCL2 B-cell CLL/lymphoma 
2
30/7,047 750/126 13/8,003
Hs.69771 CFB Complement factor B 60/5,168 320/738 35/4,561
Hs.182385 HPN hepsin 
(transmembrane 
protease, serine 1)
1,103/16 >3,257/0 60/3,685
Count: how many times a gene was ranked within top-100 by 10,000 re-samplings; Rank: rank of the gene based on its count.Page 7 of 13
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tic indexes, especially molecular markers such as HER2/
neu and Bcl-2, were unavailable and not included in the
models. Larger samples and more complete patient infor-
mation are needed to draw more decisive conclusions.
This study observed the dependence of expression profiles
on clinical indexes, especially ER status (Fig. 1). Such
dependence was caused by confounding effect of those
indexes and their unbalanced distribution between
patient groups. For instance, among the 78 patients used
in Fig. 1, 80% (35/44) of good prognosis patients were
ER-positive while the percentage was 62% (21/34) in
poor prognosis group. A partial correlation analysis was
performed and successfully controlled out ER status from
expression profile, but the confounding effect of other
indexes remained. Although the analysis can be recur-
sively applied to control out other indexes, the calculation
of residuals by Formula (2) will introduce extra variance
into the data and the expression profile obtained from
partial correlation analysis failed to achieve better per-
formance on testing patients (data not shown). As a result,
this strategy is not recommended by this study unless data
from much larger patient cohort is available. It was also
noticed that the 60-gene profiles performed better on ER-
positive patients in Veridex datasets, most likely because
the majority (68%) of training patients were ER-positive.
Hence, to get generally applicable profiles, confounders
need to be balanced not only between prognostic sub-
groups but also within the complete patient cohorts.
In reality, it is difficult for single studies to accomplish
large and fully balanced sample because of the limitation
of resource, the large number of known and unknown
confounders and their complex interaction. A more prac-
tical alternative is to diversify the clinical background and
increase the overall sample size by combining multiple
patient cohorts from different studies. A potential pitfall
of this strategy, however, is whether independently gener-
ated datasets are combinable since the systematic bias
between microarray experiments is commonly considered
substantial. The current study tested the feasibility of inte-
grated analysis by simply combining two datasets after
normalizing the expression measurements within dataset.
Profiles were objectively compared and the profiles of the
combined dataset outperformed those of the individual
datasets in most statistical analyses (Fig. 3, 5 and Table 1,
6). Furthermore, subsets of the combined dataset had bet-
ter agreement on differentially expressed genes (Fig. 4),
indicating that higher specificity of profiles was accom-
plished.
Results of this study indicated that high sensitivity of
expression profile may not be necessary: median AUC
reached a plateau when N was about 60 (Fig. 2); two
mostly different expression profiles performed similarly
in cross-validation; and more convincingly, the artificial
reduction of profile sensitivity could be tolerated to an
extensive level (Fig. 6). These results are consistent to the
studies of Fan et al [13] and Ein-Dor et al [14], which
noticed that very different profiles could significantly
agree with each other and achieve equally good predicta-
bility. This observation can be explained by gene co-
expression and the large number of genes correlated,
directly or indirectly, to prognosis. Nevertheless, higher
sensitivity may improve the robustness of profiles, which
needs further investigation in future studies. On the other
hand, profile specificity seems to be more critical. Accord-
ing to Fig. 7, performance of profiles dropped quickly
when the ratio of false positives was increased. When the
Table 6: Cox proportional hazards analysis of SEP-based classification
Training dataset Tested on all 286 patients Tested on 209 ER+ patients
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Rosetta 1.85 (1.26–2.74) 0.0019 1.97 (1.25–3.10) 0.0031
Combined 1.81 (1.23–2.66) 0.0028 2.42 (1.52–3.87) 0.0002
The 60-gene profiles obtained from the training datasets were validated by all and ER-positive patients in Veridex dataset. Patients were grouped 
using the median SEP score as threshold.
Table 5: Gene sets enriched in the combined dataset profile
Category Gene set Count p value
GO:Biological 
Process
Cell cycle/M phase of 
mitotic cell cycle
14/8 0.00008/
0.00001
BIND Myosin, heavy 
polypeptide 10, non-
muscle
5 0.01
BIND E2F transcription factor 
5, P130 binding
2 0.03
GO:Biological 
Process
Negative regulation of 
apoptosis
4 0.05
GO:Biological 
Process
Signal transduction 18 0.06
GO:Cellular 
Component
Microtubule 
cytoskeleton
4 0.07
GO:Molecular 
Function
Enzyme regulator activity 7 0.09
Category: database resource of the gene set; Count: number of genes 
overlapped by the 60-gene profile and the gene set; p value: result of 
Fisher's exact test.Page 8 of 13
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BMC Genomics 2007, 8:331 http://www.biomedcentral.com/1471-2164/8/331combined dataset profile was validated, about one-third
of the genes did not have significant differential expres-
sion in Veridex patients, suggesting that specificity of this
profile could be further improved. Furthermore,
decreased specificity made the performance of profiles
more variable (Fig. 7). For instance, while Ein-Dor et al
noticed that there were always low-ranked genes showing
quality similar to top-ranked genes, consecutive gene set
often performed differently although they should have
very close sensitivity and specificity.
It should be noted that genes indirectly correlated to prog-
nosis do not fit to a profile intended to the general popu-
lation because the observed correlation may be very
strong in some disease subtypes, but weak or even absent
in the others. The number of such 'false positives' in a pro-
file cannot be simply estimated based on p value or false
discovery rate. Instead, the ranking of genes should be
derived from diversified patient cohorts, so genes directly
and consistently correlated to disease outcome will have
their advantage. One may question the existence of such
genes and as suggested by many researchers, attempt to
identify a profile for each disease subtype. However, the
conclusion cannot be drawn before large-scale, cross-
study screening is performed.
This study applied an atypical classification of breast can-
cer patients according to their 3-year prognosis. The 5-year
Validation of expression profiles by a third datasetFigure 5
Validation of expression profiles by a third dataset. All 286 Veridex patients or 209 ER-positive patients were classified 
based on two previously derived expression profiles (Rosetta and Combined). The Kaplan-Meier survival curves corresponded 
to half of the patients who had SEP scores higher (green) or lower (red) than the median of all 286 scores. The contingency 
table, accuracy, and ROC curve area listed with plot were obtained after the Veridex patients were classified according to their 
3-year prognosis as training patients.Page 9 of 13
(page number not for citation purposes)
BMC Genomics 2007, 8:331 http://www.biomedcentral.com/1471-2164/8/331classification, however, is commonly applied mainly for
convenience, but not based on intrinsic difference of gene
expression patterns between patient groups. Beside the
support of Retsky model [15], 3-year classification may
increase the statistical power of differential expression
analysis by amplifying group difference. For instance, in
the original Rosetta dataset, 1,418 of 24,481 genes were
differentially expressed between 5-year prognosis groups
according to RST. When 3-year classification was applied,
the number of differentially expressed genes was
increased to 1,759 even though the overall sample size
was smaller (82 vs. 97). It was also shown that the expres-
sion profiles of 3-year prognosis were robust and success-
fully distinguished good and poor prognosis patients in a
third dataset (Fig. 5).
SEP was demonstrated as a valuable MPI (molecular prog-
nostic index) despite of its simple form. The parameters
(gene weights) in formula (1) are estimated independent
of each other, making SEP more robust than many other
classifiers such as Linear Discriminate Analysis, and
robustness is essential for analysis performed on inde-
pendent datasets. Unlike the suggestion of Teschendorff et
al [26], the distribution of SEP did tend to be bi-modal, or
tri-modal when confounding effect was presented (Fig. 1).
Although most analyses of this study dichotomized SEP
scores as a conservative strategy, it is possible to apply
more quantitative analysis in the future to take advantage
of SEP as a continuous variable. For instance, it was dem-
onstrated by Veridex patients that the most of highly
scored patients (>90%) had good prognosis. Such high
specificity, as suggested by van 't Veer et al [8], will help
good prognosis patients avoid unnecessary radical treat-
ments. However, we noticed that SEP scores of independ-
ent patient cohorts usually have different locations and
scales. Consequently, we could only classify Veridex
patients according to relative SEP values. Such a limitation
of SEP or similar classifier is presumably caused by tech-
nical variations between microarray datasets, especially
different array platforms. Without a common reference,
the current method will not be able to classify a single test-
ing patient before the platform and protocol of microar-
ray experiments are standardized. To achieve the direct
comparison of SEP between different patient cohorts, we
suggest that all data-generating studies about the same
topic should include one or more pairs of common refer-
ence samples.
Relationship between specificity and quality of expression profileFigure 7
Relationship between specificity and quality of 
expression profile. After each step of the reduction proce-
dure removed three genes (Fig. 6), these genes were 
replaced by three noise genes. This replacement procedure 
was repeated until all genes in the initial profile were false 
positives. The consequent changing of permutation median 
and 90% CI of ROC curve area was presented.
Relationship between sensitivity and quality of expression profileFigure 6
Relationship between sensitivity and quality of 
expression profile. Rosetta dataset was re-sampled for 
another 1,000 times. An initial 60-gene profile was obtained 
from each re-sampling. A stepwise reduction procedure was 
applied to randomly select three genes and remove them 
from the initial profile at each step. The consequent changing 
of permutation median and 90% CI of ROC curve area was 
presented.Page 10 of 13
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The current study strongly advocates the clinical value of
microarray data on breast cancer prognosis and the advan-
tage of performing expression profiling across multiple
datasets. However, the generality of profiles was dimin-
ished by the confounding effect of currently used clinical
indexes. A larger number of training patients with more
diversified and balanced clinical background should be
used by future studies to further pursue this topic.
Methods
Data processing
Two published microarray datasets, Rosetta [8] and Stan-
ford [27], were used to generate gene expression profiles
of breast cancer prognosis. Both datasets provided infor-
mation about disease outcome and clinical indexes in
addition to gene expression measurements. Breast cancer
patients were classified into two prognosis groups.
Patients who recurred within three years after mastectomy
were classified into poor prognosis group, while those
who were followed up for at least three years and kept
recurrence-free at the end of follow-up were put into good
prognosis group. Patients not fit to either group were
excluded from this study. Consequently, Rosetta dataset
included 51 good prognosis and 31 poor prognosis
patients and Stanford dataset included 25 and 37 patients
respectively. Microarray sequence features were mapped
to NCBI Unigene clusters [28], and redundant clusters
were condensed by averaging expression measurements.
Totally 5,569 clusters were presented in both datasets.
Only these genes were examined in this study. Sample/ref-
erence ratios were log10-transformed, followed by normal-
izing each patient to median equal zero and standard
deviation equal to one. To make the same genes compara-
ble to each other between different datasets, expression
measurements of each gene were also normalized to zero
median and one standard deviation separately in each
dataset [see Additional file 1].
SEP: Score for Expression Profile
A designed variable, Score for Expression Profile (SEP),
was used as a weighted linear summation of gene expres-
sion profile. Given an expression profile including N
genes, SEP score of each patient was calculated as:
SEP = ∑N[wi(Xi - Ei)] (1)
In formula (1), wi was the weight of the ith gene, a param-
eter empirically estimated based on training data. When a
statistical test was used to evaluate differential gene
expression, the resultant test statistic or its transformation,
such as correlation coefficient, Z score, or log10-trans-
formed p value, could be used as the value of w. For each
gene in the profile, the magnitude of its w should reflect
its relative weight and the sign of its w should correspond
to its direction of differential expression between sample
groups. Xi was the expression level of the ith gene in the
patient and Ei was its expected expression level estimated
from training data. When patient outcome was dichoto-
mous, Ei was the expression level that had equal probabil-
ity to be found in either sample group and could be
denoted as E (Xi | p+ = p- = 0.5).
Partial correlation analysis
A partial correlation analysis was used in this study to con-
trol the confounding effect of clinical indexes on gene-
outcome correlation. This analysis first controlled out a
confounder from expression measurements by calculating
residuals as:
Xresidual = X - E (X | Controlled Variable) (2)
In Formula (2), X was an observed expression measure-
ment and E was the expected value of X given a specific
value of the variable to be controlled, such as positive or
negative ER status. Patients were classified according to
the controlled variable and the E values of each gene were
estimated as group means. Subsequently, the partial cor-
relation coefficient (r') of each gene to disease outcome
was calculated using the residuals.
Statistical analyses
Statistical analyses of this study were carried out by R 2.4.1
computing language and environment [29]. The functions
used for analyses were: area of ROC curve – colAUC
(package: caTools); logistic regression model: lrm (pack-
age: Design); likelihood ratio test: lrtest (package: lrtest);
false discovery rate: qvalue (package: qvalue); survival
analysis – survfit (package: survival); and Cox propor-
tional hazards analysis – cph (package: Design).
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